Sign-on & Comment Letters

LUNGevity ensures that the lung cancer community’s interests are represented and heard through a variety of vehicles, including submitting and signing letters to legislators and regulators.

Access to Care

Food and Drug Administration (FDA)

Support for FDA appointment nominees and initiatives to streamline the cancer drug approval process

Right to Try Coalition Letter (House) (March 12, 2018)

Right to Try (S.204 & H.R. 878) (February 6, 2018)

Oncology Center of Excellence (OCE) (August 3, 2017)

Enhancing Patient Engagement Efforts Across FDA (June 12, 2017)

Coalition for Clinical Trials Awareness letter (April 7, 2017)

Gottlieb support letter (April 4, 2017)

Gottlieb support letter (March 13, 2017)

Oncology Center for Excellence letter (June 6, 2016)

Califf support letter (February 19, 2016)

Institute for Clinical and Economic Review (ICER)

Urging inclusion of the patient perspective in policy documents

Veterans Affairs ICER Letter (November 13, 2017)

Comment on ICER blog

Letter on ICER draft document for NSCLC (September 15, 2016)

Partnership to Improve Patient Care ICER letter (September 12, 2016)

National Institutes of Health (NIH)

Input on proposed federal rules

Letter on Patient Protection and Affordable Care Act; Market Stabilization (March 7, 2017)

Patient Support

Promoting incorporation of more patient support in policymaking

Cancer Care Planning and Communication Act, H.R. 5160 (March 14, 2018)

Friends of the Cancer Policy Institute letter (January 31, 2017)

Regulation of Lab-Developed-Tests (LTDs)

Urging policymakers to include FDA involvement in the regulation of LDTs

Letter to House (April 1, 2016)

Letter to Senate (April 1, 2016)

Letter to House (January 24, 2017)

Letter to Senate (January 24, 2017)

Research Funding


Support for coverage for screening to promote early detection of lung cancer

Letter to CMS supporting screening (October 8, 2014)

21st Century Cures

Support for the 21st Century Cures Act, a federal patient-focused bill that would advance the discovery and development of treatments, strengthen the patient voice in the research and regulatory environment, increase funding, and encourage innovation

Letter to House and Senate (November 16, 2016)